Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Gross Profit: 2021-2024

Historic Gross Profit for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to $362.3 million.

  • Kiniksa Pharmaceuticals International's Gross Profit rose 74.36% to $160.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $523.3 million, marking a year-over-year increase of 57.87%. This contributed to the annual value of $362.3 million for FY2024, which is 52.98% up from last year.
  • Kiniksa Pharmaceuticals International's Gross Profit amounted to $362.3 million in FY2024, which was up 52.98% from $236.9 million recorded in FY2023.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Gross Profit registered a high of $362.3 million during FY2024, and its lowest value of -$12.9 million during FY2022.
  • In the last 3 years, Kiniksa Pharmaceuticals International's Gross Profit had a median value of $236.9 million in 2023 and averaged $195.4 million.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Gross Profit plummeted by 143.80% in 2022 and then skyrocketed by 1,936.77% in 2023.
  • Over the past 4 years, Kiniksa Pharmaceuticals International's Gross Profit (Yearly) stood at $29.4 million in 2021, then slumped by 143.80% to -$12.9 million in 2022, then soared by 1,936.77% to $236.9 million in 2023, then soared by 52.98% to $362.3 million in 2024.